A common drug used to prevent migraines might have an additional benefit -- protecting women against stroke. Women taking the ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Additionally, headaches are the third highest cause of disability-adjusted life years globally ... for the Acute Treatment of Migraine with or without Aura in Adults. Axsome Therapeutics. January 30, ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

Phill has battled migraine for most of his life, facing debilitating visual auras, dismissive doctors, and countless ...

He had a bad headache and his right arm felt tingly and numb. He sat up in bed, and as he tried to move his fingers and toes, ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.

Concomitant treatment with triptans with serotonin–norepinephrine reuptake inhibitors (SNRIs; venlafaxine) can cause serious ... with the features of migraine without aura usually follows ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline ...

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...